Frontlight ResearchEarly access
CompletedNo phase
Salivary and Serum Leptin Levels in Oral Lichen Planus Patients: A Case-control Study.
Key facts
- Who runs it
- Cairo University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 78 people enrolled
- Started
- 30 Dec 2023
- Ended
- 30 Dec 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- Leptin
- Record updated
- 30 March 2025
Who can take part
- Age
- 30 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Ages for both sexes fall between 30 and 70
- Symptomatic OLP has been diagnosed clinically and verified histologically
- Participants who sign a written consent form after being fully informed about the study
Who cannot take part
- Treatment with a systemic or locally administered systemic medication within the previous three months before the commencement of the research
- Patients who have been diagnosed with a malignant tumor or tumors
- Patients now taking or who have just stopped taking an NSAIDs (both steroidal and non steroidal) for pain or inflammation
- Women who are expecting or nursing
- Inmates, the mentally ill, the elderly, etc, all fall into this category
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to evaluate the levels of leptin in both saliva and serum samples of patients diagnosed with oral lichen.
The 2 groups in the trial
- Oral lichen planus patients
Assessment of salivary and serum leptin levels
Treatment: Leptin
- Healthy control group
Assessment of salivary and serum leptin levels
Treatment: Leptin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Salivary and Serum Leptin Levels in Oral Lichen Planus Patients: A Case-Control Study.
- Record updated
- 30 March 2025